Table 1

Participant demographics
Characteristic Group 1 (n = 19) Group 2 (n = 16) Group 3 (n = 16) Group 4 (n = 18)
Participant demographics
Age (years) 52.04 (11.7) 50.27 (8.48) 55.65 (9.49) 55.59 (6.69)
Time since diagnosis (years) 3.39 (0.90) 2.69 (0.92) 3.19 (0.85) 3.14 (1.22)
Menopausal status*
Premenopausal 11 (58%) 11 (69%) 8 (50%) 8 (44%)
Postmenopausal 8 (42%) 5 (31%) 8 (50%) 10 (56%)
Marital status
Married 16 (84%) 10 (63%) 11 (69%) 11 (61%)
Single 3 (16%) 6 (37%) 5 (31%) 5 (39%)
Smoking history
Current smoker 1 (5%) 9 (56%) 2 (13%) 6 (33%)
Cancer details
Cancer stage
I 6 (32%) 4 (25%) 5 (31%) 4 (22%)
II 9 (47%) 9 (56%) 8 (50%) 10 (56%)
III 4 (21%) 3 (19%) 3 (19%) 4 (22%)
Estrogen receptor positive 14 (74%) 14 (88%) 14 (88%) 14 (78%)
Surgery
Wide local excision 9 (47%) 5 (31%) 10 (63%) 7 (39%)
Mastectomy 10 (53%) 11 (69%) 6 (38%) 11 (61%)
Axillary clearance 7 (37%) 9 (38%) 4 (25%) 10 (56%)
Chemotherapy 17 (90) 14 (88%) 13 (81%) 16 (89%)
Radiotherapy 15 (79) 11 (69%) 14 (88%) 16 (89%)
Hormone therapy
Tamoxifen 9 (47%) 7 (44%) 12 (75%) 7 (39%)
Aromatase inhibitor 5 (26%) 6 (38%) 2 (13%) 7 (39%)
Biological therapy
Herceptin 3 (16%) 2 (13%) 1 (6%) 2 (11%)

Data are presented as mean (standard deviation) for continuous variables and as frequency (percentage) for categorical variables.

*Refers to menopausal status at diagnosis.

Guinan et al.

Guinan et al. Nutrition Journal 2013 12:99   doi:10.1186/1475-2891-12-99

Open Data